Upcoming Events All Events

Latest News

SALT LAKE CHAMBER: Salt Lake Chamber Statement Regarding Office Invasion by Inland Port Protestors

Today Derek Miller, president and CEO of the Salt Lake Chamber, issued the following statement regarding the inland port protest at the Chamber offices: “While a full assessment of the damage is not yet complete, I want to say that fortunately our staff is safe.

DISCGENICS, INC: First Utahns Treated in Nationwide FDA-Allowed Clinical Study of Locally Developed Cell Therapy for Chronic Low Back Pain

DiscGenics, Inc., a clinical stage biotechnology company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced the first Utahns have been treated in its nationwide clinical study of IDCT, a locally developed injectable disc cell therapy for degenerative disc disease (DDD).

ARIIX: Industry-First ARIIX Founders Club Adds International Member

ARIIX, a unique and disruptive international opportunity company that promotes healthy toxin-free living, is proud to announce the addition of Wataru and Yoshimi Kanno to the ARIIX Founders Club, an industry-first approach, which grants rights and benefits to members similar to the owners of the company.

ACLU OF UTAH: ACLU of Utah Statement on Facial Recognition Searches of Utah’s Driver’s License Database by Law Enforcement

“Reports that state agencies allowed federal immigration and local law enforcement agents to run thousands of facial recognition searches using Utah’s driver’s license database is concerning to us and should be alarming to anyone who values privacy and due process.

UTAH FARM BUREAU: Farm Families Weighed down by Stress

Farm families are under increased stress this season, challenged by weather, trade issues, the farm economy and many other factors that are out of their control.

LSK BIOPHARMA: LSK Biopharma Announces Preliminary Review of Top-Line Results From Angel Study

LSK BioPharma (LSKB) has completed the unblinding and preliminary review of topline data from its ANGEL Study, a Phase III clinical trial for rivoceranib (apatinib) which enrolled 460 advanced or metastatic gastric cancer patients.

Metro Business Network